^
CANCER:
Hepatocellular Cancer
ASS1 negative
HCC
BCT-100
Sensitive
:
C3
Invest New Drugs - 3wk
No biomarker
HCC
pembrolizumab
Sensitive
:
A1
No biomarker
HCC
bevacizumab + atezolizumab
Sensitive
:
A1
No biomarker
HCC
cabozantinib tablet
Sensitive
:
A1
No biomarker
HCC
nivolumab
Sensitive
:
A1
AFP elevation
HCC
ramucirumab
Sensitive
:
A1
No biomarker
HCC
regorafenib
Sensitive
:
A1
No biomarker
HCC
lenvatinib
Sensitive
:
A1
No biomarker
HCC
sorafenib
Sensitive
:
A1
No biomarker
HCC
nivolumab + ipilimumab
Sensitive
:
A1
NTRK3 fusion
HCC
larotrectinib
Sensitive
:
A2
NTRK2 fusion
HCC
larotrectinib
Sensitive
:
A2
NTRK1 fusion
HCC
larotrectinib
Sensitive
:
A2
NTRK3 fusion
HCC
entrectinib
Sensitive
:
A2
NTRK2 fusion
HCC
entrectinib
Sensitive
:
A2
NTRK1 fusion
HCC
entrectinib
Sensitive
:
A2
No biomarker
HCC
sirolimus
Sensitive
:
A2
No biomarker
HCC
sintilimab + Byvasda (bevacizumab biosimilar)
Sensitive
:
B
AFP elevation
HCC
regorafenib
Sensitive
:
B
FGF21-H
HCC
lenvatinib
Sensitive
:
B
No biomarker
HCC
SRF388
Sensitive
:
B
HGF-H + VEGFA-H
HCC
erlotinib + sorafenib
Resistant
:
B
AFP elevation
HCC
sorafenib + LY2157299
Sensitive
:
C2
TSC2 overexpression
HCC
everolimus
Resistant
:
C3
FOXA3 overexpression
HCC
sorafenib
Sensitive
:
C3
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our